Inhibition of the Hedgehog pathway in Lung Cancer

Lung cancer is the leading cause of cancer related mortality globally and is classified as either Small Cell Lung Cancer (SCLC) or Non-Small Cell Lung Cancer (NSCLC) upon pathology review. [1,2] The main histologic types of NSCLC include squamous cell carcinoma and adenocarcinoma. [2] The majority of patients have non-curable disease stage at the time of diagnosis. Advances in systemic treatments including chemotherapy, targeted therapies and immune check point inhibitors have improved prognosis in recent years.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research

Related Links:

Conclusions: This study concludes that 68Ga Pentixafor is a promising future PET molecule for imaging CXCR4 over expression reported in lung cancer and many other human malignancies. This novel PET tracer has the potential of becoming a powerful tool for monitoring therapy response to CXCR4 inhibitors and also for the development of emerging alpha/beta targeted therapies in advanced stage lung carcinoma. $$graphic_078CAB3A-2C78-49E0-8A2E-0F11F0BF0518$$
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lung Cancer I: Molecular Biomarkers and Molecular Imaging Signatures Source Type: research
Publication date: May 2019Source: Journal of the American College of Radiology, Volume 16, Issue 5, SupplementAuthor(s): Expert Panel on Thoracic Imaging:, Patricia M. de Groot, Jonathan H. Chung, Jeanne B. Ackman, Mark F. Berry, Brett W. Carter, Patrick M. Colletti, Stephen B. Hobbs, Barbara L. McComb, Benjamin Movsas, Betty C. Tong, Christopher M. Walker, Sue S. Yom, Jeffrey P. KanneAbstractLung cancer is the leading cause of cancer-related deaths in both men and women. The major risk factor for lung cancer is personal tobacco smoking, particularly for small-cell lung cancer (SCLC) and squamous cell lung cancers, but oth...
Source: Journal of the American College of Radiology - Category: Radiology Source Type: research
Lung cancer is the leading cause of cancer-related deaths in both men and women. The major risk factor for lung cancer is personal tobacco smoking, particularly for small-cell lung cancer (SCLC) and squamous cell lung cancers, but other significant risk factors include exposure to secondhand smoke, environmental radon, occupational exposures, and air pollution. Education and socioeconomic status affect both incidence and outcomes. Non –small-cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, comprises about 85% of lung cancers.
Source: Journal of the American College of Radiology : JACR - Category: Radiology Authors: Tags: Appropriate use criteria Source Type: research
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study evaluated its diagnostic value for differentiating between NSCLC and high-grade neuroendocrine tumor (HGNET).MethodsStathmin-1 protein expression was assessed by immunohistochemistry (IHC) in surgical specimens of 414 NSCLC (305 adenocarcinoma [AD], 102 squamous cell carcinoma [SCC], 7 large-cell carcinoma [LA]), 5 typical carcinoid (TC; a low-grade neuroendocrine tumor), and 34 HGNET (17 small-cell carcinoma [SCLC] and 17 large-cell neuroendocrine carcinoma [LCNEC]) and biopsy specimens of 57 NSCLCs (29 AD and 28 SCC) and 42 HGNETs (17 LCNEC and 25 SCLC). We also analyzed stathmin-1 mRNA levels in 81 NSCLC and ...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
The soluble forms of PD-1 and PD-L1 (sPD-1, sPD-L1) were detected in the blood of patients (pts) with tumors. Evidence suggests that the blood levels of sPD-1/PD-L1 might facilitate the prediction of clinic/pathological characteristics, treatment response, and survival outcomes.Aim: to evaluate soluble sPD-L1 plasma concentrations in lung cancer (LC) pts, and their correlation with clinico-pathological characteristics and treatment response.Method: Plasma samples of 95 LC pts were examined for soluble PD-L1 blood concentration with DuoSet ELISA system.Results: M:F ratio 66:29 (69.5%:30.5%), median age of 64 years (range 30...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung Cancer Source Type: research
ConclusionCXCR4 may be a promising target for diagnostics and therapy in both SCLC and NSCLC.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Lung cancer is the leading cause of cancer-related deaths worldwide (1). The main types of lung cancer are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), accounting for 15% and 85% of the established cases respectively. NSCLC can be subdivided into two major subtypes: squamous cell carcinoma (SCC) and adenocarcinoma (AC), which differ in clinical, radiological, and histological characteristics (2). The diagnosis of early-stage lung cancer is crucial for succesful curative therapy, because treatment options and prognosis directly depend on tumour size and metastatic spread at the time of diagnosis (3).
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionCXCR4 may be a promising target for diagnostics and therapy in both SCLC and NSCLC.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: CXCR4 may be a promising target for diagnostics and therapy in both SCLC and NSCLC. PMID: 30076481 [PubMed - as supplied by publisher]
Source: Clin Med Res - Category: Research Authors: Tags: J Cancer Res Clin Oncol Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Pathology | Skin Cancer | Small Cell Lung Cancer | Squamous Cell Carcinoma